Innovative Platform RXi Pharmaceuticals focuses on developing next-generation immuno-oncology therapeutics utilizing its proprietary self-delivering RNAi platform, presenting opportunities to collaborate on cutting-edge gene therapy solutions.

Research Engagement The company's active participation in high-profile scientific conferences like the Keystone Symposia suggests a priority on advancing RNAi research, making it a potential partner for advanced molecular biology tools and research collaborations.

Growing Market Presence Having recently gone public and with annual revenues between 1 to 10 million dollars, RXi shows strong growth momentum, indicating potential for scalable partnerships in biotechnology development and therapeutics distribution.

Expertise in Immuno-oncology With a dedicated focus on immuno-oncology and collaborations with institutions such as the Karolinska Institutet, RXi is positioned to expand its therapeutic pipeline, creating sales opportunities around innovative cancer immunotherapies.

Funding & Development While specific funding figures are not detailed, RXi's development stage and strategic hires highlight ongoing investment in R&D, opening avenues for partnership in auxiliary technologies, research tools, and specialized biotech services.